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Pharmacy Law Brief: 
The Federal False Claims Act 
Author: Joseph L. Fink III, B.S.Pharm., J.D., Professor of Pharmacy Law and Policy and Kentucky Pharmacists Associ-
ation Professor of Leadership, Department of Pharmacy Practice and Science, UK College of Pharmacy 
Question:   I continually see mention of a federal law 
known as the Federal False Claims Act and, in association 
with that, read strange phrases and words such as “Quit 
Tam Action” and “Relator.” What is all that? 
Response:   The Federal False Claims Act (FCA) is a 
federal statute that creates potential criminal and civil liabil-
ity for those who would defraud the federal government. 
This can apply either to individuals or to companies. The 
contemporary statute traces its origins to the Civil War 
when a variety of vendors sold defective or adulterated 
products to the federal government. Enactment of this stat-
ute during the administration of President Lincoln has re-
sulted in this sometimes being referred to as the “Lincoln 
Law.” It can be found at 31 U.S.C. §3729. 
One unusual feature of the statute is that it permits or au-
thorizes individuals having no affiliation with the federal 
government to initiate legal actions on behalf of the govern-
ment when they have knowledge of nefarious activities that 
might run afoul of the law. These people are sometimes 
referred to as “whistleblowers” and the resultant filings are 
called whistleblower lawsuits.  
If the lawsuit is successful the person who filed the suit, 
referred to by the title “relator,” can be rewarded with 15-30 
percent of the amount recovered. This provision authorizing 
an individual to file the lawsuit on behalf of the federal gov-
ernment and creating the entitlement to a portion of the 
amount recovered is called the qui tam provision. Those 
two words are a key portion of a long legal phrase in Latin 
that essentially means “he who sues in this matter for the 
king as well as for himself.” 
Two of the key provisions in the False Claims Act serve to 
prohibit [1] knowingly presenting, or causing to be present-
ed, a false claim for approval or payment, and [2] knowingly 
making, using or causing to be made or used, a false rec-
ord or statement materials to a false or fraudulent claim. So 
either making the false claim or crafting documents to justi-
fy or support that false submission can run afoul of the law. 
It should be borne in mind that the statute mandates treble 
damages plus the court can impose additional penalties of 
between $5,500 and $11,000 per false claim.  
There have been interesting shifts with the statute over 
time. During the Civil War the transgressions that first led to 
enactment of the statute primarily related to sales of materi-
el to the federal government for prosecuting the war. That 
focus on military-related purchase continued for quite some 
time. In fact, during World War II the statute was enacted to 
reduce the share of proceeds directed to the relator. Up 
through the 1980s the activities of defense contractors con-
tinued to be a principle focus of FCA-related activities. It is 
noteworthy, however, that by the late 1990s that focus had 
shifted to health care fraud. It is reported that false claims 
related to provision of health care goods and services now 
comprise a majority of cases filed under the statute.  
The pharmaceutical industry, pharmacy chains and individ-
ual pharmacies have all come under scrutiny using the Fed-
eral False Claims Act. During recent years GlaxoSmithKline 
entered into a $750 million settlement with federal govern-
ment under the False Claims Act and Ranbaxy Pharmaceu-
ticals paid a $500 million settlement, both for allegedly re-
leasing adulterated medications into interstate commerce. 
The Department of Justice reports that the pharmaceutical 
industry was one of the largest contributors to settlements, 
with the predominant violation being alleged off-label pro-
motional activities. Advent of Part D of Medicare with more 
direct, expanded federal payment for pharmaceuticals and 
pharmacy services has increased potential exposure in this 
area.  
Submit Questions: jfink@uky.edu 
Disclaimer:  The information in this column is intended 
for educational use and to stimulate professional discus-
sion among colleagues. It should not be construed as legal 
advice. There is no way such a brief discussion of an issue 
or topic for educational or discussion purposes can ade-
quately and fully address the multifaceted and often com-
plex issues that arise in the course of professional prac-
tice. It is always the best advice for a pharmacist to seek 
counsel from an attorney who can become thoroughly fa-
miliar with the intricacies of a specific situation, and render 
advice in accordance with the full information. 
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Between 2009 and 2012 the federal government recovered 
$9.5 billion under this statute. In FY 2013 alone the U.S. De-
partment of Justice recovered $3.8 billion in civil settlements 
and judgments under the FCA. Of that total, $2.9 billion was 
recovered through qui tam actions. There were 752 qui tam 
actions filed during FY 2013, over 100 more than during the 
previous year.  
